Victory Capital Management Inc. Acquires New Shares in Savara Inc (NASDAQ:SVRA)

Victory Capital Management Inc. acquired a new stake in shares of Savara Inc (NASDAQ:SVRA) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 12,115 shares of the company’s stock, valued at approximately $39,000.

Several other institutional investors also recently modified their holdings of the business. Jane Street Group LLC boosted its position in shares of Savara by 22.0% during the fourth quarter. Jane Street Group LLC now owns 20,757 shares of the company’s stock valued at $32,000 after buying an additional 3,746 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Savara by 25.0% during the third quarter. Renaissance Technologies LLC now owns 70,000 shares of the company’s stock valued at $109,000 after buying an additional 14,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Savara in the first quarter worth about $32,000. Millennium Management LLC boosted its position in Savara by 12.3% in the second quarter. Millennium Management LLC now owns 156,314 shares of the company’s stock worth $238,000 after purchasing an additional 17,093 shares during the last quarter. Finally, Citigroup Inc. purchased a new position in Savara in the fourth quarter worth about $33,000. 97.28% of the stock is owned by hedge funds and other institutional investors.

Savara Trading Down 3.4 %

Shares of NASDAQ:SVRA opened at $3.66 on Tuesday. The stock has a market capitalization of $494.73 million, a price-to-earnings ratio of -13.07 and a beta of 0.80. The company has a debt-to-equity ratio of 0.30, a quick ratio of 18.33 and a current ratio of 18.33. The stock’s 50-day simple moving average is $3.63 and its two-hundred day simple moving average is $3.18. Savara Inc has a 52-week low of $1.08 and a 52-week high of $4.21.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, August 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Analysts expect that Savara Inc will post -0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their target price on Savara from $3.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, August 14th.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.